在血液性恶性瘤中检查点抑制
Aaron Tsumura1, Daniel Levis2, Joseph M Tuscano1,2
1Division of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA, United States.
Frontiers in oncology
|November 3, 2023
概括
针对CTLA-4和PD-1/PD-L1通路的免疫检查点抑制剂在血液恶性瘤,特别是霍奇金淋巴瘤中表现有前途. 对于高风险髓状腺癌,如抗CD47封锁等新型目标正在出现.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 检查点抑制剂治疗,包括针对CTLA-4和PD-1/PD-L1的单克隆抗体,已经彻底改变了癌症治疗,特别是在固体瘤中.
- 虽然霍奇金淋巴瘤已经显示出显著的临床益处,检查点抑制在其他血液恶性瘤的应用正在扩大,特别是在复发/耐药设置.
研究的目的:
- 在过去十年中,回顾最近的发展和免疫检查点抑制血液恶性瘤的进展.
- 突出检查点抑制剂的新兴治疗目标和协同应用.
主要方法:
- 审查最近的科学文献和关于免疫检查点抑制剂在血液恶性瘤的临床数据.
- 对FDA批准的单克隆抗体药物和新检查点路径目标的分析.
主要成果:
- 检查点抑制剂已在霍奇金淋巴瘤中表现出有效性,并且在其他血液恶性瘤中表现出实用性,特别是在复发/耐药病例中.
- 检查点抑制可以与其他疗法 (如造血干细胞移植) 协同作用.
- 新兴的标,如抗CD47阻断,对高风险的骨髓质疏松综合征和TP-53突变性急性髓性白血病有希望.
结论:
- 在利用免疫检查点抑制用于血液性恶性瘤方面取得了重大进展.
- 进一步的研究对于优化这些药物的使用和探索新的治疗策略至关重要.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Role of Hematopoietic Growth Factors
1.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K


